Literature DB >> 22289986

Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring.

E Dander, G Lucchini, P Vinci, M Introna, F Masciocchi, P Perseghin, A Balduzzi, S Bonanomi, D Longoni, G Gaipa, D Belotti, M Parma, A Algarotti, C Capelli, J Golay, A Rovelli, A Rambaldi, A Biondi, E Biagi, G D'Amico.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22289986     DOI： 10.1038/leu.2011.384

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  25 in total

1.  Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells.

Authors:  L C J Te Boome; C Mansilla; L E van der Wagen; C A Lindemans; E J Petersen; E Spierings; K A Thus; K Westinga; M Plantinga; M Bierings; A E C Broers; M L H Cuijpers; G W van Imhoff; J J Janssen; C Huisman; S Zeerleder; G Huls; J J Boelens; N M Wulffraat; I C M Slaper-Cortenbach; J Kuball
Journal:  Leukemia       Date:  2015-04-03       Impact factor: 11.528

Review 2.  Role of mesenchymal stem cells in leukaemia: Dr. Jekyll or Mr. Hyde?

Authors:  Rebecca S Y Wong; Soon-Keng Cheong
Journal:  Clin Exp Med       Date:  2013-06-23       Impact factor: 3.984

Review 3.  Mesenchymal stromal cells in the antimicrobial host response of hematopoietic stem cell recipients with graft-versus-host disease--friends or foes?

Authors:  A Balan; G Lucchini; S Schmidt; A Schneider; L Tramsen; S Kuçi; R Meisel; P Bader; T Lehrnbecher
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

4.  Serum-free spheroid suspension culture maintains mesenchymal stem cell proliferation and differentiation potential.

Authors:  Stella Alimperti; Pedro Lei; Yuan Wen; Jun Tian; Andrew M Campbell; Stelios T Andreadis
Journal:  Biotechnol Prog       Date:  2014-03-21

5.  Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation.

Authors:  Jeffery J Auletta; Saada K Eid; Patiwet Wuttisarnwattana; Ines Silva; Leland Metheny; Matthew D Keller; Rocio Guardia-Wolff; Chen Liu; Fangjing Wang; Theodore Bowen; Zhenghong Lee; Luis A Solchaga; Sudipto Ganguly; Megan Tyler; David L Wilson; Kenneth R Cooke
Journal:  Stem Cells       Date:  2015-02       Impact factor: 6.277

Review 6.  CDH2 and CDH11 act as regulators of stem cell fate decisions.

Authors:  Stella Alimperti; Stelios T Andreadis
Journal:  Stem Cell Res       Date:  2015-02-19       Impact factor: 2.020

7.  Bone marrow mesenchymal stromal cells drive protective M2 microglia polarization after brain trauma.

Authors:  Elisa R Zanier; Francesca Pischiutta; Loredana Riganti; Federica Marchesi; Elena Turola; Stefano Fumagalli; Carlo Perego; Emanuela Parotto; Paola Vinci; Pietro Veglianese; Giovanna D'Amico; Claudia Verderio; Maria-Grazia De Simoni
Journal:  Neurotherapeutics       Date:  2014-07       Impact factor: 7.620

8.  Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation.

Authors:  Giovanna Lucchini; Erica Dander; Fabio Pavan; Irene Di Ceglie; Adriana Balduzzi; Paolo Perseghin; Giuseppe Gaipa; Alessandra Algarotti; Martino Introna; Alessandro Rambaldi; Attilio Rovelli; Andrea Biondi; Ettore Biagi; Giovanna D'Amico
Journal:  Stem Cells Int       Date:  2012-05-30       Impact factor: 5.443

9.  Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children.

Authors:  Joanne Kurtzberg; Susan Prockop; Sonali Chaudhury; Biljana Horn; Eneida Nemecek; Vinod Prasad; Prakash Satwani; Pierre Teira; Jack Hayes; Elizabeth Burke
Journal:  Biol Blood Marrow Transplant       Date:  2020-02-07       Impact factor: 5.742

10.  Are cultured mesenchymal stromal cells an option for immunomodulation in transplantation?

Authors:  Jan A Plock; Jonas T Schnider; Riccardo Schweizer; Vijay S Gorantla
Journal:  Front Immunol       Date:  2013-02-26       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.